Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine Combined with Doxycycline for Chronic Endometritis
NCT07180563Phase 2
Key facts
- Status
- Recruiting
- Start
- Mar 2025
- Primary completion
- Nov 2026
- Countries
- 1
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- Small Molecules
- Drugs
- berberine
- Conditions
- endometritis
01
Overview
Phase 2, randomised, open-label trial of berberine in endometritis (2 arms), sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Cure rate of chronic endometritis at 1 month. Started Mar 2025; status: recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
Berberine + Doxycycline
Berberine hydrochloride + Doxycycline hydrochloride
Doxycycline
Doxycycline hydrochloride monotherapy
03
Who it enrols
Females of childbearing age (>= 20 years) diagnosed with chronic endometritis by CD138 immunohistochemistry. Excludes patients with G6PD deficiency, hemolytic anemia, or hypersensitivity to the study drugs.
04
Endpoints
Primary
Cure rate of chronic endometritis
Secondary
Number of CD138 positives per 10 high-power fields
Recurrence rate of uterine polyps
Number and size of uterine polyps recurrence
Beyond the preview
Go deeper on NCT07180563.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07180563.